Recombinant Human IL-8/CXCL8 Protein Best Seller

R&D Systems, part of Bio-Techne | Catalog # 208-IL

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Carrier Free
208-IL-010/CF
208-IL-050/CF
Catalog #
Availability
Size / Price
Qty
With Carrier
208-IL-010
208-IL-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

  • R&D Systems E. coli-derived Recombinant Human IL-8/CXCL8 Protein (208-IL)
  • Quality control testing to verify active proteins with lot specific assays by in-house scientists
  • All R&D Systems proteins are covered with a 100% guarantee

Source

E. coli

Accession #

P10145.1

Conjugate

Unconjugated

Applications

Bioactivity

View all IL-8/CXCL8 Proteins and Enzymes »

Product Specifications

Source

E. coli-derived human IL-8/CXCL8 protein
Ser28-Ser99

Purity

>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ser28

Predicted Molecular Mass

8 kDa

Activity

Measured by its ability to chemoattract BaF3 mouse pro-B cells transfected with human CXCR2.
The ED50 for this effect is 0.5-2.5 ng/mL.

Reviewed Applications

Read 8 reviews rated 4.9 using 208-IL in the following applications:

Scientific Data Images for Recombinant Human IL-8/CXCL8 Protein

Recombinant Human IL-8/CXCL8 Protein Bioactivity

Recombinant Human IL-8/CXCL8 Protein Bioactivity

Recombinant Human IL-8/CXCL8 (Catalog # 208-IL) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR2. The ED50 for this effect is 0.5-2.5 ng/mL.
Recombinant Human IL-8/CXCL8 Protein SDS-PAGE

Recombinant Human IL-8/CXCL8 Protein SDS-PAGE

1 μg/lane of Recombinant Human IL-8/CXCL8 was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a single band at 8 kDa.

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 208-IL
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
Carrier Free: 208-IL/CF
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.

Background: IL-8/CXCL8

Interleukin-8 (IL-8), also known as CXCL8, GCP-1, and NAP-1, is a widely expressed proinflammatory member of the CXC family of chemokines. Near its N-terminus, this 8-9 kDa chemokine contains an ELR motif which is important for its angiogenic properties (1). IL-8/CXCL8 can associate into a homodimer or a heterodimer with CXCL4/PF4 (2), and it can also interact with matrix and cell surface glycosaminoglycans (3). Mature human IL-8/CXCL8 shares 65%-69% amino acid (aa) sequence identiity with canine, feline, and porcine IL-8/CXCL8 (4). There is no IL-8/CXCL8 gene counterpart in rodent. N-terminal truncation by multiple proteases generates a range of shorter forms, and an alternative splice form of human IL-8/CXCL8 carries an eleven aa substitution at the C-terminus (5). The bioactivity of IL-8/CXCL8 is regulated by these truncations, by IL-8/CXCL8 citrullination at Arg5 (N-terminal to the ELR motif) (6), and by the decoy receptor DARC (7). IL-8/CXCL8 effects are mediated through CXCR1/IL-8 RA, which is also used by CXCL6, and through CXCR2/IL-8 RB, which is used by multiple CXC chemokines (1). CXCR1 and CXCR2 associate into functional homodimers and heterodimers with each other (8). Through both CXCR1 and CXCR2, CXCL8 promotes neutrophil adhesion to the vascular endothelium and migration to sites of inflammation (9). It triggers the antimicrobial activation of neutrophils through CXCR1 (10). CXCL8 also binds to Serpin A1/alpha-1 Antitrypsin, and this prevents IL-8/CXCL8 interaction with CXCR1 (11). IL-8/CXCL8 is upregulated in atherosclerotic lesions and other cardiac pathologies where it exacerbates inflammatory tissue damage (12). In addition, it induces VEGF expression, vascular endothelial cell proliferation, angiogenesis, and tumor cell invasiveness (13-16).

References

  1. Lazennec, G. and A. Richmond (2010) Trends Mol. Med. 16:133.
  2. Nesmelova, I.V. et al. (2005) J. Biol. Chem. 280:4948.
  3. Pichert, A. et al. (2012) Biomatter 2:142.
  4. Schmid, J. and C. Weissmann (1987) J. Immunol. 139:250.
  5. Mortier, A. et al. (2008) Pharmacol. Ther. 120:197.
  6. Proost, P. et al. (2008) J. Exp. Med. 205:2085.
  7. Neote, K. et al. (1994) Blood 84:44.
  8. Munoz, L.M. et al. (2009) J. Immunol. 183:7337.
  9. Gerszten, R.E. et al. (1999) Nature 398:718.
  10. Jones, S.A. et al. (1996) Proc. Natl. Acad. Sci. USA 93:6682.
  11. Bergin, D.A. et al. (2010) J. Clin. Invest. 120:4236.
  12. Apostolakis, S. et al. (2009) Cardiovasc. Res. 84:353.
  13. Martin, D. et al. (2009) J. Biol. Chem. 284:6038.
  14. Li, A. et al. (2005) Angiogenesis 8:63.
  15. Waugh, D.J. and C. Wilson (2008) Clin. Cancer Res. 14:6735.
  16. Fernando, R.I. et al. (2011) Cancer Res. 71:5296.

Long Name

Interleukin 8

Alternate Names

CXCL8, GCP1, IL8, LAI, LECT, LUCT, LYNAP, MDNCF, MONAP, NAF, NAP1, NCF, TCF, TSG1

Entrez Gene IDs

3576 (Human); 396880 (Porcine); 403850 (Canine); 493836 (Feline)

Gene Symbol

CXCL8

UniProt

P10145.1

Additional IL-8/CXCL8 Products

Product Documents for Recombinant Human IL-8/CXCL8 Protein

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS 208-IL (with carrier)
Download SDS 208-IL/CF (carrier free)

Product Specific Notices for Recombinant Human IL-8/CXCL8 Protein

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2026 Bio-Techne. All Rights Reserved. All trademarks and registered trademarks are the property of Bio-Techne and its brands unless otherwise specified.